Over three million Americans suffer from severe emphysema, a form of COPD (Chronic Obstructive Pulmonary Disease). This chronic, debilitating disease causes irreversible damage to delicate lung tissue, leading to shortness of breath and reduced capacity to manage activities of daily living, leading to diminished quality of life.
El Camino Hospital is collaborating with the Palo Alto Medical Foundation to conduct a clinical trial to evaluate the investigational use of the RePneu® (say‘RENEW’) Lung Volume Reduction Coil (LVRC) for patients experiencing symptoms of emphysema.
How does the RePneu LVRC work? The LVRC is implanted in the airways of the lung and works by compressing the diseased lung tissue, creating more room for healthier areas of the lung to expand and function.
It is also designed to help restore the lung's natural elasticity and prevent airway collapse, making it easier for patients to breathe.
- Over 35 years of age
- Diagnosed with emphysema
- Experiencing increasing difficulty with simple daily tasks
- Stopped smoking for at least eight weeks
- Completion of pulmonary rehabilitation program within six months and/or on maintenance program
Enrollment and more information:
For enrollment information visit the Fogarty Clinical Research website or call Juliet Wilson, the study coordinator, at 650-962-4463. For more general information please visit www.ClinicalTrials.gov or www.pneumrx.com/usa.
In collaboration with Palo Alto Medical Foundation for Health Care, Research and Education.